Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 219

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 219
---
:                        |     |                    |            |   |     |      |            |   |
| Issuance of Class D Common Stock Warrants in connection with the February 2024 Public Offering |     | $                  |          — |   |     | $    |  6,269,684 |   |
| Alternative cashless exercise of Class C Common Stock Warrants                                 |     | $                  |          — |   |     | $    |     57,589 |   |
| Alternative cashless exercise of Class F Common Stock Warrants                                 |     | $                  |  3,094,680 |   |     | $    |          — |   |

See accompanying notes to the condensed consolidated financial statements. F-31 REVELATION BIOSCIENCES, INC. Notes to the Unaudited Condensed Consolidated Financial Statements 1. Organization and Basis of Presentation Revelation Biosciences, Inc. (collectively with its wholly-owned subsidiaries, referred to as “we,” us,” “our,” “Revelation,” or the “Company”) is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention for acute kidney injury (“AKI”), GEM-CKD as a treatment for chronic kidney disease (“CKD”), and GEM-PSI as a prevention for post surgical infection (“PSI”) (together the “Product Candidates”). The Company was incorporated in the state of Delaware on November 20, 2019 (originally as Petra Acquisition, Inc.) and is based in San Diego, California. The Company’s common stock and public warrants are listed on the Nasdaq Capital Market under the symbols “REVB” and “REVBW”, respectively. Reverse Stock Split On January 28, 2025, the Company effected the approved 1-for-16reverse stock split of our shares of common stock. Unless specifically provided otherwise herein, the share and per share information that follows in this Quarterly Report, reflects the effect of the reverse stock split. Liquidity and Capital Resources Going Concern The Company has incurred recurring losses since its inception, including a net loss of $ 2.1million for the three months ended March 31, 2025. As of March 31, 2025, the Company had an accumulated deficit of $ 42.6million, a stockholders’ equity of $ 2.